281 related articles for article (PubMed ID: 25143389)
1. Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) transcription factors.
Nair V; Sreevalsan S; Basha R; Abdelrahim M; Abudayyeh A; Rodrigues Hoffman A; Safe S
J Biol Chem; 2014 Oct; 289(40):27692-701. PubMed ID: 25143389
[TBL] [Abstract][Full Text] [Related]
2. Metformin inhibits pancreatic cancer cell and tumor growth and downregulates Sp transcription factors.
Nair V; Pathi S; Jutooru I; Sreevalsan S; Basha R; Abdelrahim M; Samudio I; Safe S
Carcinogenesis; 2013 Dec; 34(12):2870-9. PubMed ID: 23803693
[TBL] [Abstract][Full Text] [Related]
3. Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells.
Soares HP; Ni Y; Kisfalvi K; Sinnett-Smith J; Rozengurt E
PLoS One; 2013; 8(2):e57289. PubMed ID: 23437362
[TBL] [Abstract][Full Text] [Related]
4. Benzyl Isothiocyanate (BITC) Induces Reactive Oxygen Species-dependent Repression of STAT3 Protein by Down-regulation of Specificity Proteins in Pancreatic Cancer.
Kasiappan R; Jutooru I; Karki K; Hedrick E; Safe S
J Biol Chem; 2016 Dec; 291(53):27122-27133. PubMed ID: 27875298
[TBL] [Abstract][Full Text] [Related]
5. Specificity protein (Sp) transcription factors and metformin regulate expression of the long non-coding RNA HULC.
Gandhy SU; Imanirad P; Jin UH; Nair V; Hedrick E; Cheng Y; Corton JC; Kim K; Safe S
Oncotarget; 2015 Sep; 6(28):26359-72. PubMed ID: 26317792
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of NFkappaB and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein down-regulation.
Jutooru I; Chadalapaka G; Lei P; Safe S
J Biol Chem; 2010 Aug; 285(33):25332-44. PubMed ID: 20538607
[TBL] [Abstract][Full Text] [Related]
7. Metformin-induced anticancer activities: recent insights.
Safe S; Nair V; Karki K
Biol Chem; 2018 Mar; 399(4):321-335. PubMed ID: 29272251
[TBL] [Abstract][Full Text] [Related]
8. Betulinic acid inhibits colon cancer cell and tumor growth and induces proteasome-dependent and -independent downregulation of specificity proteins (Sp) transcription factors.
Chintharlapalli S; Papineni S; Lei P; Pathi S; Safe S
BMC Cancer; 2011 Aug; 11():371. PubMed ID: 21864401
[TBL] [Abstract][Full Text] [Related]
9. Curcumin and synthetic analogs induce reactive oxygen species and decreases specificity protein (Sp) transcription factors by targeting microRNAs.
Gandhy SU; Kim K; Larsen L; Rosengren RJ; Safe S
BMC Cancer; 2012 Nov; 12():564. PubMed ID: 23194063
[TBL] [Abstract][Full Text] [Related]
10. Transcription factors specificity protein and nuclear receptor 4A1 in pancreatic cancer.
Safe S; Shrestha R; Mohankumar K; Howard M; Hedrick E; Abdelrahim M
World J Gastroenterol; 2021 Oct; 27(38):6387-6398. PubMed ID: 34720529
[TBL] [Abstract][Full Text] [Related]
11. Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation.
Abdelrahim M; Baker CH; Abbruzzese JL; Safe S
J Natl Cancer Inst; 2006 Jun; 98(12):855-68. PubMed ID: 16788159
[TBL] [Abstract][Full Text] [Related]
12. Specificity Protein Transcription Factors and Cancer: Opportunities for Drug Development.
Safe S; Abbruzzese J; Abdelrahim M; Hedrick E
Cancer Prev Res (Phila); 2018 Jul; 11(7):371-382. PubMed ID: 29545399
[TBL] [Abstract][Full Text] [Related]
13. Drugs that target specificity proteins downregulate epidermal growth factor receptor in bladder cancer cells.
Chadalapaka G; Jutooru I; Burghardt R; Safe S
Mol Cancer Res; 2010 May; 8(5):739-50. PubMed ID: 20407012
[TBL] [Abstract][Full Text] [Related]
14. Tanshinone IIA can inhibit MiaPaCa‑2 human pancreatic cancer cells by dual blockade of the Ras/Raf/MEK/ERK and PI3K/AKT/mTOR pathways.
Su CC
Oncol Rep; 2018 Nov; 40(5):3102-3111. PubMed ID: 30226540
[TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide downregulates specificity protein (Sp) transcription factors and inhibits bladder cancer cell and tumor growth.
Jutooru I; Chadalapaka G; Sreevalsan S; Lei P; Barhoumi R; Burghardt R; Safe S
Exp Cell Res; 2010 Aug; 316(13):2174-88. PubMed ID: 20435036
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of rhabdomyosarcoma cell and tumor growth by targeting specificity protein (Sp) transcription factors.
Chadalapaka G; Jutooru I; Sreevalsan S; Pathi S; Kim K; Chen C; Crose L; Linardic C; Safe S
Int J Cancer; 2013 Feb; 132(4):795-806. PubMed ID: 22815231
[TBL] [Abstract][Full Text] [Related]
17. mTOR inhibition induces EGFR feedback activation in association with its resistance to human pancreatic cancer.
Wei F; Zhang Y; Geng L; Zhang P; Wang G; Liu Y
Int J Mol Sci; 2015 Feb; 16(2):3267-82. PubMed ID: 25654224
[TBL] [Abstract][Full Text] [Related]
18. Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition.
Charette N; De Saeger C; Lannoy V; Horsmans Y; Leclercq I; Stärkel P
Mol Cancer; 2010 Sep; 9():256. PubMed ID: 20860815
[TBL] [Abstract][Full Text] [Related]
19. Metformin, an antidiabetic agent reduces growth of cutaneous squamous cell carcinoma by targeting mTOR signaling pathway.
Chaudhary SC; Kurundkar D; Elmets CA; Kopelovich L; Athar M
Photochem Photobiol; 2012; 88(5):1149-56. PubMed ID: 22540890
[TBL] [Abstract][Full Text] [Related]
20. Metformin reduces pancreatic cancer cell proliferation and increases apoptosis through MTOR signaling pathway and its dose-effect relationship.
Zhao HW; Zhou N; Jin F; Wang R; Zhao JQ
Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5336-5344. PubMed ID: 32495867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
